|
Oct 9
|
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
|
|
Aug 30
|
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
|
|
Aug 28
|
HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 21
|
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
|
|
Jul 29
|
HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
|
|
May 24
|
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
|
|
May 17
|
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
|
|
May 17
|
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
|
|
May 14
|
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
|
|
May 14
|
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
|
|
Apr 5
|
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
|
|
Jan 11
|
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
|
|
Dec 1
|
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
|
|
Nov 9
|
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
|
|
Sep 18
|
Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics
|